At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Clinical Response to Rhinovirus Challenge in Human Asthmatics
In Brief
A Phase 2 clinical trial evaluating Rhinovirus (GMP RV16 HRV-16) for Asthma and Allergic Rhinitis. Completed, enrolled 38 participants across 1 site.
Detailed Summary
Rhinovirus (RV) infections represent the most common cause of asthma exacerbations in children and adolescents. The investigators hypothesize that the immune responses generated in the nose of allergic rhinitics and asthmatics underlie subsequent systemic modulation of the immune system, and that - in susceptible individuals (i.e., those with pre-existing asthma) - this modified nasal milieu is responsible for the asthma exacerbation. Open label single center study in asthmatics as well as allergic rhinitis (AR) and healthy controls. All subjects will undergo good manufacturing practice (GMP) RV16 inoculation and responses will be compared between the 3 cohorts.
Study Details
Timeline
Interventions
300 tissue culture infectious dose (TCID)50 mg/ml intranasal one time only